




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07K 14/47, 1/00, A61K 38/17, G01N 33/68, C12P 21/08, C07K 16/18, A61K 51/08</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/05394</b> <b>(43) International Publication Date:</b> 23 February 1995 (23.02.95)
<b>(21) International Application Number:</b> PCT/GB94/01802 <b>(22) International Filing Date:</b> 17 August 1994 (17.08.94)  <b>(30) Priority Data:</b> 9317120.5 17 August 1993 (17.08.93) GB  <b>(71) Applicants (for all designated States except US):</b> ROYAL POSTGRADUATE MEDICAL SCHOOL [GB/GB]; Hammersmith Hospital, Du Cane Road, London W12 0NN (GB). BIRKBECK COLLEGE [GB/GB]; Mallet Street, London WC1E 7HX (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PEPYS, Mark, Brian [GB/GB]; Immunological Medicine Unit, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0NN (GB). BLUNDELL, Thomas, Lean [GB/GB]; Birkbeck College, Mallet Street, London WC1E 7HX (GB).  <b>(74) Agents:</b> SILVESTON, Judith et al.; Abel & Imray, Northumberland House, 303-306 High Holborn, London WC1V 7LH (GB).		<b>(81) Designated States:</b> AM, AT, AT (Utility model), AU, BB, BG, BR, BY, CA, CH, CN, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), ES, FI, FI (Utility model), GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SK (Utility model), TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** THERAPEUTIC AND DIAGNOSTIC AGENTS FOR AMYLOIDOSIS**(57) Abstract**

Therapeutical and diagnostic agents for amyloidosis comprise molecules that inhibit the binding of serum amyloid P component to amyloid fibrils or analogues or homologues of the amyloid binding site on serum amyloid P component. The resolution of the complete three dimensional structure of serum amyloid P component enables inhibitors, binding site analogues and homologues to be designed by computer-aided molecular modelling.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### **THERAPEUTIC AND DIAGNOSTIC AGENTS FOR AMYLOIDOSIS**

The present invention relates to therapeutic and diagnostic agents for amyloidosis. The invention also  
5 relates to the three-dimensional structure of human serum amyloid P component and to the use of that structure in the production of therapeutic and diagnostic agents.

Amyloidosis is the abnormal deposition of autologous proteins as insoluble fibrils in tissues. There are many  
10 different forms, each associated with a different fibril protein. Although microscopic amyloid deposition is always present in the elderly, and rarely causes clinical problems, more substantial amyloidosis, especially in the vital organs, is associated with progressive, untreatable and  
15 usually fatal disease. The most common disorders associated with amyloidosis are Alzheimer's disease and maturity onset diabetes mellitus. Other forms of acquired and hereditary amyloidosis are rarer but cause serious morbidity and are generally fatal.

20 Serum amyloid P component (SAP), a normal human plasma protein, is a universal constituent of amyloid deposits in all forms of amyloidosis, including the cerebral amyloid of Alzheimer's disease [1], as a result of its specific calcium-dependent binding affinity for amyloid fibrils [2].  
25 The role, if any, of SAP in the pathogenesis or persistence of amyloid *in vivo* is not known and amyloid fibrils can be generated *in vitro* from suitable precursor proteins in the absence of SAP. However, SAP in amyloid is identical to its normal circulating form, it is not catabolised in the  
30 deposits in contrast to its normal rapid uptake from the circulation and catabolism in hepatocytes, and it is itself highly resistant to proteolytic degradation.

Human serum amyloid P component is a decameric plasma glycoprotein composed of identical subunits non-covalently  
35 associated in two pentameric rings interacting face-to-face. Although SAP is not required for amyloid fibrillogenesis *in vitro*, it may protect the fibrils from degradation *in vivo* [3]. SAP is also the major DNA and chromatin binding protein of plasma [4,5] and other autologous ligands for SAP

include fibronectin, C4-binding protein [6] and glycosamino-  
glycans [7]; SAP is also a normal tissue matrix constituent  
associated with elastic fibres [8] and the glomerular  
basement membrane [9]. Finally, SAP is a calcium-dependent  
5 lectin, the best characterised ligand of which is the 4,6-  
cyclic pyruvate acetal of  $\beta$ -D-galactose (MOBDG) [10].

Human SAP shows no polymorphism or heterogeneity of its  
protein or its glycan [11] and no individual deficient in  
SAP has yet been described, suggesting that the molecule has  
10 important functions. Furthermore, SAP and C-reactive  
protein (CRP), the classical acute phase protein with which  
it shares over 50% sequence identity, belong to the  
pentraxin family of plasma proteins which have been stably  
conserved throughout vertebrate evolution [12,13]. The  
15 structure and structure-function relationships of SAP are  
thus of considerable fundamental interest, in addition to  
their clinical importance which arises from the invaluable  
new information provided by use of radio-labelled SAP as a  
specific quantitative *in vivo* tracer for amyloid deposits  
20 [14]. The speed and specificity with which SAP from the  
circulation localises to amyloid deposits and its prolonged  
retention there make SAP an interesting targeting agent. As  
indicated above, however, in spite of various observations  
and speculations, the role if any of SAP in the pathogenesis  
25 and persistence of amyloid *in vivo* was not known.

The present invention is based on our complete  
resolution of the three-dimensional structure of SAP, and  
also on our demonstration that the binding of SAP *in vitro*  
to amyloid fibrils at a specific binding site protects those  
30 fibrils from proteolytic degradation in the presence of  
proteinases. Results obtained on amyloid development *in vivo*  
confirms the *in vitro* results. We believe, therefore, that  
SAP is needed for amyloidogenesis, possibly to protect newly  
formed fibrils from proteolysis. Inhibition or reversal of  
35 the binding of SAP to fibrils will expose those fibrils to  
destruction, for example, by macrophages and/or released  
proteinases. Inhibition or reversal of binding of SAP to

amyloid fibrils (either newly synthesised fibrils or established fibrils) may therefore be used for the treatment and/or prophylaxis of amyloidosis, including Alzheimer's disease.

5       Accordingly, the present invention provides a molecule, especially a physiologically tolerable molecule, that inhibits the binding of serum amyloid P component to amyloid fibrils. The inhibition may be competitive or non-competitive, and may be reversible or irreversible. The  
10       mechanism of inhibition may be via direct inhibition with the ligand binding site of SAP or it may be allosteric. A molecule of the invention may be regarded either as an SAP inhibitor or as an SAP ligand. The term "inhibition of binding of SAP to amyloid fibrils" as used herein includes  
15       both the prevention of such binding and also the reversal of binding that has already occurred.

      The present invention also provides an analogue or homologue of the binding site for amyloid fibrils on SAP and further provides a low molecular weight polypeptide or other  
20       molecule having a high affinity for amyloid fibrils. Such a substance (binding site analogue or homologue or high affinity molecule) should preferably have greater affinity for amyloid fibrils than does SAP. The use of such a  
binding site analogue or homologue or molecule having a high  
25       affinity for amyloid fibrils, particularly a substance that has a higher affinity for amyloid fibrils than does SAP itself will inhibit, prevent or reverse the binding of SAP to amyloid fibrils, for example, it will displace SAP from the fibrils. Provided the binding site analogue or  
30       homologue or molecule having high affinity for amyloid fibrils does not have proteinase resistance and/or does not confer protection against proteinase activity to the amyloid fibrils (at least not to the same extent as does SAP), such substances may be used in the treatment or prophylaxis of  
35       amyloidosis.

      Any method of detecting or determining inhibition of binding of one molecule to another molecule may be used to

identify a molecule that inhibits binding of SAP to amyloid fibrils; a detailed Protocol of one such test is given in Example 1. Further tests include the effects on the inhibition by SAP of proteolytic digestion of amyloid  
5 fibrils obtained ex vivo or produced in vitro from synthetic  $\beta$ -protein. Such methods are described generally below and in detail in Example 2.

Such tests may be also used to determine the ability of a binding site analogue or homologue or of a high affinity  
10 substance to bind to amyloid fibrils, for example, by investigating the binding to amyloid fibrils of a radio-labelled candidate molecule in an analogue of the protocol given in Example 1 below, for assessing potential inhibitors. (The term "high affinity substance" is used to  
15 denote a low molecular weight polypeptide or other molecule having a high affinity for amyloid fibrils, preferably an affinity greater than that of SAP. "High affinity" generally denotes binding in the micromolar to nanomolar range.)

20 The invention also provides a pharmaceutical preparation which comprises a physiologically tolerable molecule of the invention, for example, an inhibitor, binding site analogue or homologue or high affinity substance, in admixture or conjunction with a  
25 pharmaceutically suitable carrier. The invention also provides such a molecule of the present invention for use as a medicament, especially for the treatment or prophylaxis of amyloidosis, and further provides the use of such a molecule for the manufacture of a medicament for the treatment or  
30 prophylaxis of amyloidosis, especially Alzheimer's disease.

As described below, the molecules of the invention, especially the binding site analogues and homologues and high affinity substances, may also be used for in vivo diagnostic imaging.

35 Candidate molecules for testing for inhibition of SAP binding to amyloid fibrils may be selected at random, or may be chosen or designed on the basis of similarity to

compounds known to inhibit such binding, for example, MOBDG and phosphoethanolamine (PE). However, such a screening strategy inevitably has a low success rate; it is time-consuming and the results are unpredictable.

- 5 Our resolution of the three-dimensional structure SAP, including the structure and topology of various binding sites, including the putative amyloid binding site, enables compounds to be designed specifically, and so leads to a much higher success rate. The design of candidate
- 10 inhibitors of amyloid fibril binding and of binding site analogues and homologues and high affinity substances may be carried out by any of the well-known methods of molecular modelling, for example, computer-aided molecular design (CAMD). Candidate molecules are then synthesised and tested
- 15 by an in vitro assay for their ability to inhibit the binding of SAP to amyloid fibrils or to function as a binding site analogue or homologue or high affinity substance. If desired, a molecule synthesised on the basis of a CAMD can be modified, for example, chemically and the
- 20 modified molecules screened for their binding ability using the tests described herein.

A molecule of the present invention may belong to any class of chemical provided it achieves the desired effect. For example, an inhibitor or high affinity molecule may be a

25 polypeptide or peptide, an oligonucleotide, an oligosaccharide or any type of organic chemical. Even small molecules may be effective, c.f., phosphoethanolamine. A binding site analogue or homologue is generally a polypeptide. A molecule of the invention may be a

30 naturally-occurring substance or may be derived from such a substance. A molecule of the present invention may be synthesised de novo, for example, by combinatorial chemistry or may be designed by molecular modelling.

The present invention therefore includes all novel

35 molecules that inhibit the binding of SAP to amyloid fibrils or that are binding site analogues or homologues or that are high affinity substances, including for example, those

obtained by molecular modelling and synthesis and those obtained by combinatorial chemistry.

The invention also includes the use of substances known per se, for example, for other purposes, in the prevention, reversal or inhibition of the binding of SAP to amyloid fibrils and hence in the treatment of amyloidosis, especially Alzheimer's disease and maturity onset diabetes mellitus. The invention further provides use of a molecule according to the present invention for the manufacture of a medicament for the prevention, reversal or inhibition of the binding of SAP to amyloid fibrils and hence for the manufacture of a medicament for the treatment or prophylaxis of amyloidosis, especially Alzheimer's disease and maturity onset diabetes mellitus.

For use in treatment or diagnosis in vivo a molecule of the present invention must be physiologically tolerable. A molecule that is not physiologically tolerable may be used in in vitro investigations of amyloidosis and its treatment.

It will be appreciated that a candidate molecule will be synthesised by a method appropriate for that type of molecule, for example, an organic chemical compound will be synthesised chemically; a protein or peptide may be obtained by synthesis from amino acids or by recombinant DNA technology.

As described briefly above, we have now convincingly demonstrated that SAP does indeed protect amyloid fibrils from digestion by proteinases and does so exclusively by binding to them rather than acting as an enzyme inhibitor. We have also shown that SAP binds to amyloid fibrils at the MOBDG binding site.

Amyloid fibrils of AA (reactive systemic), AL (monoclonal IgG light chain) and apoAI (apoprotein AI) type were isolated from the organs of patients dying from amyloidosis and were shown to be digested during incubation at 37°C in vitro with the proteolytic enzymes, for example, pronase, trypsin and chymotrypsin. Digestion was monitored by analysis of the incubation mixtures in reduced SDS-PAGE



and also by release of trichloroacetic acid (TCA)-soluble radioactivity when the fibrils had been oxidatively labelled with  $^{125}\text{I}$ . Incubation of such labelled fibrils with cultured monocyte-derived macrophages also led to digestion.

5        In all cases addition of highly purified SAP to the incubation mixtures, under conditions in which the SAP could bind to the fibrils, resulted in greatly reduced fibril digestion. This inhibition was dose and time-dependent and was not observed when other proteins, C-reactive protein  
10 (CRP) and human serum albumin, were added as controls in place of SAP. CRP is a particularly good control since its structure is extremely similar to that of SAP, and it shares the same remarkable proteinase resistance, but it does not bind to amyloid fibrils and had no effect on their  
15 digestion. When albumin was used as the control protein both it and the fibrils were completely digested by the proteinases.

         However, we found that the protective effect of SAP was completely abrogated when MOBDG was included in the  
20 incubation mixtures. This low molecular weight specific ligand of SAP competitively inhibits binding of SAP to amyloid fibrils, as we have previously reported [3,10]. The presence of SAP in the incubation mixtures thus had no effect on proteolysis of the fibrils when it was prevented  
25 from binding to them by the presence of MOBD.

         Since SAP binds to all types of amyloid fibrils in vivo we conclude that SAP is also likely to prevent the fibrils from being degraded in vivo by cells, such as macrophages, and/or released proteinases. Agents capable of inhibiting  
30 or reversing the binding of SAP to amyloid fibrils in vivo will therefore facilitate and accelerate digestion and removal of the fibrils, leading to clearance of amyloid deposits and remission of their clinical and pathological effects.

35        We have now also demonstrated that SAP undergoes typical calcium-dependent binding to amyloid fibrils produced in vitro from synthetic  $\beta$ -protein.  $\beta$ -protein is

the subunit of the amyloid fibrils which are deposited in the brain and cerebral blood vessels in Alzheimer's disease (AD). Evidence linking  $\beta$ -protein amyloidosis in the brain to the pathogenesis of AD is now very powerful [54]. We have now shown that SAP protected the  $\beta$ -protein amyloid fibrils from proteolysis in precisely the same fashion as it protected the ex vivo fibrils, and the protection was completely abrogated by MOBDG. Furthermore, exactly the same results have been obtained using ex vivo amyloid fibrils isolated from the brain of a patient with Alzheimer's disease. A drug capable of exercising the same effect in vivo within the brain will therefore confer great therapeutic benefit in AD.

In a separate line of investigation we have studied the capacity of mice deprived of SAP to develop AA amyloidosis in an accelerated model of amyloidogenesis. Amyloid was induced rapidly by intravenous injection of an extract of amyloidotic spleen (so-called amyloid enhancing factor) together with a single profound acute phase stimulus (subcutaneous injection of silver nitrate) [59]. All control animals developed appreciable splenic amyloidosis within 48 h. In contrast all mice in which circulating SAP had been completely removed by administration of adequate doses of sheep anti-mouse SAP antiserum failed to develop any detectable amyloid deposits. A further control group which received sheep antiserum to mouse C3, an unrelated serum protein not involved in amyloidosis, almost all developed amyloid.

The sheep antisera were raised by immunisation with the respective isolated pure mouse proteins [62,63]. The IgG fraction, separated by DEAE-Sephacel ion exchange chromatography, was used for injection into the mice.

These in vivo studies confirm that the mechanism of action of the anti-mouse SAP is indeed via SAP depletion, and show that SAP is required for amyloidogenesis. This may reflect the need for SAP to protect newly formed fibrils from proteolysis, as indicated by the work on protection of

fibrils from proteolysis described above, or there may be a direct role for SAP in amyloid fibrillogenesis which has not previously been suspected. In any case the results again focus attention on inhibition of SAP binding to amyloid  
5 fibrils as a most attractive target for therapeutic attack in all forms of amyloidosis. A suitable inhibitory agent will act prophylactically to prevent development of the common age-associated diseases caused by amyloid deposition, especially AD and type II (maturity onset) diabetes  
10 mellitus.

Recently we reported the crystallisation of SAP in conditions that induce a reversible dissociation of the decamer into a pentameric form [15]. We now report the X-ray analysis of the crystals at 2Å resolution, defining  
15 the complete three-dimensional structure of the pentamer. Intriguingly this human plasma protein has a tertiary fold which resembles that of the legume C-type lectins, concanavalin A and pea lectin. There are two calcium sites and these are shown to be involved in binding of  
20 carbohydrate and the synthetic ligand phosphoethanolamine. However, the calcium sites in SAP and the calcium and manganese sites of concanavalin A differ in their relationship to the common topology. The SAP pentamer shows nearly perfect five-fold symmetry and sequence comparisons  
25 suggest that very similar interactions are retained in CRP pentamers.

As indicated above, the present invention is based in part on the resolution of the complete three-dimensional structure of SAP, which is described in detail below. The  
30 knowledge of the structure of SAP, especially the key ligand binding sites, enables the design of therapeutic and diagnostic agents.

The present invention provides a method of designing molecules having a particular structural relationship to a  
35 protein molecule, especially to an active site or a binding site of the protein, the method utilising the three-dimensional structure of the protein, characterised in that

the protein molecule is human SAP. The present invention also provides the use of the three-dimensional structural model of human SAP as the basis for molecular modelling of molecules having a particular structural relationship with human SAP.

The present invention also provides a method of producing a molecule having a structural relationship to a protein molecule, the method comprising (i) using the three-dimensional structure of the protein as the basis for the design of the molecule, and then (ii) synthesising the molecule thus-designed, characterised in that the protein is serum amyloid P component and the molecule produced binds to the amyloid fibril binding site on SAP or binds to amyloid fibrils.

The invention further provides a method for the production of a molecule that inhibits the binding of serum amyloid P component to amyloid fibrils, that is a binding site analogue or homologue or that is a high affinity substance, which comprises carrying out computer-aided molecular design using the three-dimensional structure of serum amyloid P component, synthesising the molecules thus designed and testing the molecules for the ability to inhibit binding of serum amyloid P component to amyloid fibrils and/or the ability to bind to amyloid fibrils.

In a method of the present invention candidate molecules are generally tested for their ability to inhibit binding of serum amyloid P component to amyloid fibrils in vitro or to bind to amyloid fibrils in vitro, for example, using an assay method as described in detail in Example 1 herein or a modification thereof if binding to amyloid fibrils is to be tested.

In a method of the invention, candidate molecules may be obtained by carrying out computer-aided molecular design using the three-dimensional structure of serum amyloid P component, in particular the three-dimensional structure at and/or around the various binding sites and other sites described in more detail below, and then synthesising the

molecules so-designed. One or more of the following are preferably used in the design of a candidate molecule: the final refined electron density of serum amyloid P component described herein and illustrated in Figure 1; the ribbon  
5 drawing described herein and illustrated in Figure 2; hydrogen bonding diagrams set out in Figure 3; and one or more of the calcium and ligand binding sites described herein and illustrated in Figure 5.

A molecule according to the present invention having a  
10 particular structural relationship with human SAP may be an analogue of an SAP ligand, for example, a ligand analogue capable of interacting specifically and with high affinity to the ligand binding site of SAP and most especially with the amyloid binding site. Alternatively, the molecule may  
15 be an analogue or a homologue of an SAP binding site, most especially the amyloid binding site, or another molecule having high affinity for amyloid fibrils.

The design of molecules having a particular structural relationship to part of a protein molecule, so-called  
20 "molecular modelling" is well established, see for example [16-20]. Any such method may be used according to the present invention.

With increasing power and decreasing prices, computers powerful enough for molecular modelling are now readily  
25 available commercially, for example, Evans and Sutherland and Silicon Graphics machines. Likewise, software packages are also available, for example, LEAPFROG (available from Tripos Associates, 16995 Hanley Road, Suite 303, St. Louis, MO 63144, USA), which suggests improvements to existing  
30 proposed molecules (OPTIMIZE), proposes new molecules expected to have good binding (DREAM) and supports interactive design (GUIDE). LEAPFROG is part of a larger software package involving protein modelling capabilities encoded in COMPOSER, which has been written by  
35 Professor Tom Blundell and colleagues at Birkbeck College, London, and is also available from Tripos Associates. COMPOSER is itself part of a comprehensive package known as

SYBYL for computer modelling and design aimed at the pharmaceutical industry. Use of such software enables modelling of related proteins to assist the understanding of the specificity of the calcium mediated binding of

5 pentraxins. Molecular modelling is becoming more and more widely used. The techniques generally used involve detailed investigations of the shape, charge distribution and the distribution of hydrophobic groups, ionic groups and hydrogen bonding at the site of interest. Automated systems

10 available commercially greatly facilitate such investigations and assist in the design of molecules having particular desired characteristics. Alternatively, a ligand that is competitive with a natural ligand may be designed.

In the present case, the process of the structure-based

15 design starts from the knowledge of the three-dimensional structures of SAP particularly when complexed to the ligands PE (phosphoethanolamine) and especially MOBDG (4,6-O-(1-carboxyethylidene)- $\beta$ -D-galactopyranoside). The binding site of the ligand MOBDG is particularly important because our

20 work has shown that binding of SAP to amyloid fibrils is inhibited by MOBDG, that is to say, MOBDG binds at or near the amyloid binding site of SAP.

The three-dimensional structure is illustrated in Figures 1 to 5 of the accompanying drawings and is described

25 in detail below. The ligands MOBDG and PE bind via calcium atoms. Knowledge of the calcium binding site is therefore important, as is the topology of patches of basic residues adjacent to the calcium binding site, which patches may be also involved in binding larger molecules, for example,

30 amyloid fibrils or DNA. Calcium (1) is co-ordinated to the side-chains of Asp58, Asn59, Glu136, Asp138 and the main chain carboxyl of Gln37, as shown in Figs. 5a and 5b. The topology at and around the region of the calcium binding site is therefore particularly important in the design of

35 therapeutic and diagnostic agents.

Structure-based design begins by delineating the surface of SAP that interacts with MOBDG (and PE) and which

may be involved in the more extensive interactions with amyloid. The structure at that region is described in detail below. The shape, charge distribution and the distribution of hydrophobic groups and hydrogen bonding in that region are determined in detail. That information enables the design of ligands, in particular those that form hydrogen bonds to the hydroxyl groups of Tyr64 and Tyr75. Such design may be carried out using appropriate computer hardware and software, as described above, for example, using an Evans and Sutherland or Silicon Graphics machine and commercially available software packages, for example, COMPOSER. Use of appropriate software enables visualisation of the molecular interactions.

A second approach involves greater analysis of the surface binding characteristics of SAP. A range of automated methods are available for exploring binding sites for hydrophobic and ionic groups and to design molecules that will bind to binding sites and to active sites. An example of suitable software for this purpose is the LEAPFROG unit of COMPOSER, which suggests improvements to existing proposed molecules (OPTIMIZE), proposes new molecules expected to have good binding (DREAM) and supports interactive design (GUIDE). COMPOSER enables modelling of related proteins to assist the understanding of the specificity of the calcium-mediated binding of pentraxins.

As indicated above, molecular modelling may be used to design molecules that inhibit the binding of serum amyloid P component to amyloid fibrils. By investigating the binding sites, for example, the MOBDG (and PE) binding site, and the calcium binding site specific inhibitory ligands may be designed. The in vitro investigations described above show that MOBDG inhibits the binding of SAP to amyloid fibrils. The putative amyloid fibril binding site is therefore at or in the region of the MOBDG binding site. MOBDG binds via calcium atoms, so the calcium binding site, described in detail herein and illustrated in Figures 5a and 5b, is a particularly suitable site for molecular modelling. The

regions of basic residues adjacent to the calcium binding site may be involved in the binding of molecules larger than MOBDG, for example, amyloid fibrils, so the region around the calcium site may also be used in molecular modelling.

- 5       A molecule of the present invention may therefore be a molecule which interacts with serum amyloid P component at and/or around the calcium binding site illustrated in Figures 5a and 5b. Such a molecule may, for example, interact with one or more of the residues Asp58, Asn59, Glu136, Asp138 and Gln37 of human serum amyloid P component or with the equivalent residues in serum amyloid P component of another species and/or with one or more basic residues in the region of those residues.

- 15       A molecule of the present invention is preferably bound with high affinity by SAP. For example, a molecule of the present invention may advantageously be based on the interactions of MOBDG with SAP but have more interactions with SAP (at or around the calcium binding site) than does MOBDG.

- 20       A molecule of the present invention may form hydrogen bonds to the hydroxyl groups of Tyr64 and Tyr75 of human serum amyloid P component or the equivalent residues in serum amyloid P component of another species.

- 25       A molecule of the present invention may be a physiologically tolerable structural analogue of a serum amyloid P component ligand, for example, of MOBDG or of phosphoethanolamine.

- 30       A further type of molecule of the present invention is one that causes inhibition of SAP binding to amyloid fibrils not by binding at the ligand binding site but by an allosteric reaction, which causes the binding site to be non-functional. The use of a binding inhibition assay, for example, as described in Example 1 below, reveals such molecules.

- 35       The use of a molecule of the present invention will result inter alia in removal or displacement of SAP from amyloid deposits and should then enable the body to mobilise



and remove the amyloid fibrils, a process which has been shown to occur if new amyloid fibril synthesis is halted [21-25].

Knowledge of the ligand binding sites, especially as described above, enables analogues and homologues of those binding sites to be produced. The term "homologue of a binding site" is used herein to denote a peptide or polypeptide structure that is identical to a native SAP binding site or that differs from the native structure by conservative substitutions only (homology). Such a peptide or polypeptide may be synthetic or recombinant. A homologue of a ligand binding site will generally be a linear sequence that is identical or homologous to a native sequence and that folds into the correct conformation. However, a homologue of a ligand binding site may also be a topological homologue, that is to say, the amino acid sequence of the homologue comprises residues that form the three-dimensional structure of the binding site but that are not contiguous in the native linear sequence.

An analogue of a ligand binding site is a structure that is capable of binding the ligand even though it bears no likeness to the native binding site. An analogue may mimic the three-dimensional structure of the binding site or may bind the ligand in some other way. An analogue may comprise an amino acid sequence or may comprise other chemical entities, for example, nucleic acids, sugars or synthetic organic chemical molecules. Generally applicable methods for making analogues of structures are known, for example, as "combinatorial chemistry" see, for example [60].

The essential requirement of any analogue or homologue of the present invention is that it is capable of binding to amyloid fibrils. Examples of preferred binding sites for the production of analogues and homologues are the calcium binding site of serum amyloid P component illustrated in Figures 5a and 5b, and an analogue or homologue preferably includes structures around the calcium binding site, especially patches of basic residues.

The present invention also provides a low molecular weight polypeptide or any other molecule, for example, an oligonucleotide or oligosaccharide or small organic molecule that has high affinity for amyloid fibrils. Such

5 polypeptides and other molecules may be designed on the basis of the three-dimensional structure of SAP or may be obtained by screening candidate molecules obtained either on the basis of a stereochemical relationship to SAP or by non-selective searching of libraries of synthetic, recombinant

10 or naturally-occurring chemical compounds. Such libraries may be produced by combinatorial chemistry. Again, the efficacy of candidate molecules can be assessed using an inhibition assay, for example, as described in Example 1 below. It is necessary that any such polypeptide or other

15 high affinity molecule to be used in vivo and also any binding site analogue or homologue to be used in vivo should not have the proteinase resistance and the protective capacity of SAP itself.

Antibodies that bind selectively to a ligand binding

20 site of SAP and that inhibit SAP binding to amyloid are also part of the present invention. Such antibodies may be monoclonal antibodies or antibody fragments generated by chemical or recombinant techniques.

Any of the various embodiments of the present invention

25 (a binding site inhibitor ligand, a binding site analogue or homologue, a low molecular weight polypeptide or other molecule having high affinity for amyloid fibrils or an antibody) that is physiologically tolerable and that inhibits binding of SAP to amyloid fibrils or that displaces

30 SAP from amyloid fibrils may be used as a medicament according to the present invention. Such agents are useful for the treatment and/or prophylaxis of amyloidosis of any form, particularly common age-associated disease caused by amyloid deposition, for example, Alzheimer's disease and

35 type II (maturity onset) diabetes mellitus.

Such agents may also be used as molecular delivery systems for the localization of other pharmaceutically active compounds at amyloid fibrils.

Administration of such an agent of the invention as a therapeutic agent or as a molecular delivery system may be enteral or parenteral. The oral route is generally preferred, provided the agent is not inactivated in the  
5 gastro-intestinal tract. (The oral route is generally unsuitable for the administration of proteins and polypeptides.) For diagnostic imaging such an agent, carrying an appropriate imaging label (see below), is generally administered intravenously or intrathecally.

10 For oral administration an agent of the present invention in admixture or conjunction with a pharmaceutically suitable carrier is preferably brought into unit dosage form, for example, as tablets, hard gelatin capsules or soft gelatine capsules. For parenteral  
15 administration, for example, by the intravenous or intrathecal route, an agent of the invention may be admixed with a suitable carrier, for example, a sterile isotonic solution or may be provided in lyophilised form. It may be necessary to take particular care with a diluent for use  
20 with a lyophilised imaging agent. Methods for preparing pharmaceutical preparations of all types, and suitable carriers and other ingredients for use in pharmaceutical preparations are well known and are described, for example, in Martindale's Extra Pharmacopoeia.

25 The present invention also includes a method of treatment and/or prophylaxis of amyloidosis, which comprises administering an effective amount of a physiologically tolerable binding site inhibitor ligand, a binding site analogue or homologue, a low molecular weight polypeptide  
30 or other molecule having high affinity for amyloid fibrils or an antibody of the present invention to a subject having or susceptible to amyloidosis.

A further aspect of the present invention is the in vivo diagnosis of amyloidosis. For this purpose a  
35 physiologically tolerable binding site inhibitor ligand, a binding site analogue or homologue, a low molecular weight polypeptide or other molecule having high affinity for amyloid fibrils or an antibody of the present invention is

labelled with a tracer that is detectable in vivo. Such tracers are well known and include radioisotopes of iodine, indium and technetium, for example  $^{123}\text{I}$ ,  $^{131}\text{I}$ ,  $^{124}\text{I}$ ,  $^{111}\text{In}$  and  $^{99\text{m}}\text{Tc}$ . Magnetic resonance tracers are also suitable. The  
5 labelled compound is administered to the patient, generally intravenously or intrathecally, and the patient is then subjected to the appropriate imaging process, and the labelling, if any, of amyloid deposits is noted for use in diagnosis.

10 Particularly useful for diagnostic purposes are molecules according to the present invention that are capable of crossing the blood-brain barrier and hence of labelling amyloid deposits in the brain, thus enabling diagnosis of Alzheimer's disease. At present there is no  
15 diagnostic test for this, the fourth most common cause of death in the Western world. Low molecular weight polypeptides or other high affinity low molecular weight molecules may be designed specifically to cross the blood-brain barrier. (Low molecular weight polypeptides may  
20 comprise, for example, 3 to 50 amino acid residues. Other high affinity low molecular weight molecules may have a mass of, for example, up to 5000 to 6000 Daltons.) Such peptides and other molecules are much cheaper than natural SAP and obviate all the problems associated with isolation, safety  
25 and availability of the human blood protein. Those problems have hitherto prevented SAP being taken up as a commercial product in spite of its undeniable clinical value, and the use of SAP in diagnosis is currently confined to research centres.

30 A further use for analogues and homologues of SAP binding sites is for the screening of potential therapeutic agents, for example, using a test for inhibition of binding to amyloid fibrils.

As indicated above, by investigating the binding sites,  
35 for example, the MOBDG and PE binding site, ligands may be designed that, for example, have more interactions with SAP than do MOBDG or PE. Such ligands will bind to SAP with higher affinity and so function as competitive ligands with

regard to amyloid and thereby remove SAP from amyloid. Removal of SAP from the deposits may then enable the body to mobilise and remove the amyloid fibrils, a process which has been shown to occur if new amyloid fibril synthesis is  
5 halted [21-25].

Synthetic or recombinant proteins homologous or analogous to the ligand binding site of native SAP may be designed as may other molecules having high affinity for amyloid fibrils. Such molecules should also be capable of  
10 displacing SAP from amyloid and provide a protective effect.

As indicated above, the knowledge of the SAP binding site enables synthetic binding site homologues and analogues to be designed. Such molecules will facilitate greatly the use of the unique amyloid binding properties to target  
15 potential therapeutic agents into amyloid deposits. They may also be used to screen potential therapeutic agents. Furthermore, they may be used as immunogens in the production of monoclonal antibodies according to the method of Köhler & Milstein [61] and subsequent modifications,  
20 which antibodies may themselves be used in diagnosis and/or therapy.

#### *Brief Description of the drawings*

- FIGURE 1: Final refined electron density map of SAP.
- 25 Figure 1a: Refined electron density map (2Fo-Fc) calculated at 2Å resolution and contoured at 1 r.m.s.
- Figure 1b: MOBDG complexed with SAP contoured at 1 r.m.s. electron density level at 2.9Å resolution.
- Figure 1c, Phosphoethanolamine (PE) complexed with SAP  
30 contoured at 1 r.m.s. electron density level at 2.9Å resolution.
- FIGURE 2: Ribbon drawings generated with Setor [26].
- Figure 2a, The topology of SAP compared with the legume C-type lectin concanavalin A (conA).
- 35 Figure 2b, Structure of the pentamer of SAP viewed along the non-crystallographic five-fold axis of symmetry.
- FIGURE 3: Hydrogen bonding diagrams generated by HERA [27] for SAP (above) and

- 20 -

pea lectin (Brookhaven code 2LTN) (below).

FIGURE 4: Alignment of the sequences of the pentraxins (one protomer sappm and one pentamer sapp) of SAP, human C-reactive protein (hcrp), hamster SAP (female hamster protein) (1fhp) and *Limulus* CRP (1lim) with the sequences of legume lectins,

5 concanavalin A (3cna) and pea lectin (2ltm and 1lte).

FIGURE 5: The calcium and ligand binding sites in SAP:

Figure 5a, Topology around the calcium binding site showing the residues involved in calcium coordination and those in the hydrophobic pocket.

Figure 5b, MO $\beta$ DG binding site.

10 FIGURE 6: Effect of SAP at concentrations of 0 to 500  $\mu$ g/ml on pronase digestion of Alzheimer's  $\beta$ -protein amyloid fibrils.

FIGURE 7: Effect of SAP at concentrations of 0 to 50  $\mu$ g/ml on pronase digestion of  $^{125}$ I-AA amyloid fibrils.

FIGURE 8: Effect of SAP at concentrations of 0 to 500  $\mu$ g/ml on pronase digestion of  
15  $^{125}$ I-AA amyloid fibrils.

FIGURE 9: Abrogation by MO $\beta$ DG of proteinase protection by SAP.

#### *Detailed Description of the drawings (Figures 1 to 5)*

Note: Figures 6 to 9 are described in detail in Example 2 below.

20 FIGURES 1a, 1b and 1c:

Final refined electron density of SAP. *a*, Refined electron density map (2Fo-Fc) calculated at 2 $\text{\AA}$  resolution and contoured at 1 r.m.s. This illustrates the SAP helix packing against the  $\beta$ -pleated sheets in the region of the disulphide bridge Cys36-Cys95. The top left hand of the diagram illustrates a region where the side chain Glu167  
25 contacts the calcium binding site of a symmetry-related molecule. The region of the calcium ions is contoured at 5 r.m.s. showing that the glutamate bridges the two ions in a manner similar to the acetate ion. *b*, MO $\beta$ DG complexed with SAP contoured at 1 r.m.s. electron density level at 2.9 $\text{\AA}$  resolution. Crystals of SAP prepared by the batch method [15] in the presence of MO $\beta$ DG were isomorphous with crystals of native SAP  
30 and had cell dimensions  $a=69.06\text{\AA}$ ,  $b=99.3\text{\AA}$ ,  $c=96.75\text{\AA}$  and  $\beta=95.84^\circ$ . Data were collected on a MAR imaging plate system mounted on a Siemens XP-18 rotating anode and a final  $R_{\text{Merge}}$  of 5.3% was obtained. Data were 95.8% complete to 2.9 $\text{\AA}$  resolution.

- 21 -

A final crystallographic R factor of 0.197 for all reflections in the range 10-2.9Å was obtained after refinement in XPLOR without non-crystallographic restraints. The success of this experiment depended on soaking in an excess of the sugar in order to displace the acetate ion which otherwise occupies the same position at the calcium-binding site. The MOβDG is well defined only in protomer 3, shown here, where it is involved in a crystal contact. c, Phosphoethanolamine (PE) complexed with SAP contoured at 1 r.m.s. electron density level at 2.9Å resolution. Crystals of SAP prepared by the batch method [15] in the presence of 9 mM PE were not isomorphous with crystals of native SAP and had cell dimensions  $a=67.05\text{\AA}$ ,  $b=103.43\text{\AA}$ ,  $c=102.43\text{\AA}$  and  $\beta=95.73^\circ$ , in space group  $P2_1$ . Data were collected on a MAR imaging plate system mounted on a Siemens XP-18 rotating anode and a final  $R_{\text{Merge}}$  of 6.4% was obtained. Data were 95.5% complete to 2.9Å resolution. In the initial refinement the SAP pentamer was treated as single rigid body and R factor of 0.332 was obtained for the 3513 reflections between 30-6Å. The five subunits were then treated as individual rigid bodies and refinement produced an R factor of 0.264 for the 11628 reflections between 18-4Å. The final crystallographic R factor of 0.199 for all reflections in the range 10-2.9Å was obtained after refinement in XPLOR; non-crystallographic symmetry restraints were not applied.

## FIGURES 2a and 2b:

Ribbon drawings generated with Setor [26]. a, The topology of SAP compared with the legume C-type lectin concanavalin A (conA). The strands are labelled from the N-terminus of SAP, ABCDEFGHIJKLMNO, with structurally equivalent strands in conA labelled similarly. The positions of the N- and C- termini in conA are altered with respect to the nascent protein by ligation of the original N- and C- termini and proteolytic cleavage between strands D and E. The two structures can be superimposed by a least squares fit using the C $\alpha$  positions of the two sets of anti-parallel sheets to produce an r.m.s. deviation of 2.4Å. This is due to a greater angle between these sheets in SAP than conA. b, Structure of the pentamer of SAP viewed along the non-crystallographic five-fold axis of symmetry. The pairwise r.m.s. deviations for all main chain atoms range from 0.19Å between protomers 1 and 5 to 0.24Å between protomers 3 and 4.

- 22 -

## FIGURE 3:

Hydrogen bonding diagrams generated by HERA [27] for SAP (above) and pea lectin (Brookhaven code 2LTN) (below). The secondary structural elements were assigned according to the criteria defined by Kabsch and Sander [29].

5

## FIGURE 4:

Alignment of the sequences of the pentraxins (one protomer sapm and one pentamer sapp) of SAP, human C-reactive protein (hcrp), hamster SAP (female hamster protein) (1fhp) and *Limulus* CRP (1lim) with the sequences of legume lectins, concanavalin A (3cna) and pea lectin (2ltm and 1lte). These alignments are based on comparing the three-dimensional structure of SAP with those of the C-type legume lectins [29]. Key to JoY alignments [30]: Solvent inaccessible, UPPER CASE X; solvent accessible, lower case x; positive  $\phi$ , *italic x*; cis-peptide, breve x; hydrogen bond to other sidechain, tilde ; hydrogen bond to mainchain amide, **bold x**; hydrogen bond to mainchain carbonyl, underline x; disulphide bond, cedilla ; metal binding sites in SAP and conA, \*; residues of SAP involved in inter-protomer contacts ¶.

10

15

## FIGURES 5a and 5b:

The calcium and ligand binding sites in SAP. Diagrams generated using Setor [26]

Important interactions between calcium ions, ligands and the protein are shown by dotted lines. *a*, Topology around the calcium binding site showing the residues involved in calcium coordination and those in the hydrophobic pocket, (Leu62, Tyr64, Tyr74) and the cleavage site (Phe144, Asp145) in SAP. Calcium (1) has heptagonal coordination, whilst Calcium (2) has hexagonal coordination. *b*, MO $\beta$ DG binding site.

The main interaction involves coordination between the calcium ions and the carboxylate of the carboxyethylidene ring. The amide nitrogens of Asn59 and Gln148 form hydrogen bonds to the 4,6 oxygens of the carboxyethylidene ring. The only interaction between the protein and the galactopyranoside ring is a hydrogen bond between the 3 oxygen and the amide nitrogen of Gln148.

20

25

*Three-dimensional structure*

Serum amyloid P component was isolated at greater than 99% purity from



- 23 -

pooled human ascites and pleural effusion fluids [31]. The crystals obtained at pH 5.5 in a medium containing calcium and acetate ions as described earlier [15] were of space group  $P2_1$  and cell dimensions  $a = 68.9\text{\AA}$ ,  $b = 99.3\text{\AA}$ ,  $c = 96.7\text{\AA}$  and  $\beta = 95.9^\circ$ . The initial model of pentameric SAP was based on X-ray analysis at  $2.8\text{\AA}$  resolution using the multiple isomorphous replacement (MIR) technique followed by solvent flattening [32] and five-fold molecular averaging [33]. The refinement statistics are shown in Table 1, the legend of which gives further details of the X-ray analysis. The final model was refined at  $2.0\text{\AA}$  resolution to an agreement (R) value of 0.18 to give a clear electron density for all residues of the five subunits (see Fig. 1a).

10        The SAP pentamer consists of five subunits of 204 amino acid residues, each with a closely similar three-dimensional structure constructed from anti-parallel  $\beta$ -strands (A-O) arranged in two sheets as shown in Fig. 2a. The tertiary fold can be envisaged as a jellyroll of strands ABCDKLNO, elaborated by the addition of three further anti-parallel strands (EFG and HIJ) forming a  $\beta$ -meander at the same end of each of the sheets to give the topology: +11-9+7-1-1-1-3+1+1+5-9-1+12-13. In this arrangement strands A and M are both hydrogen bonded to strand L as shown in Fig. 3. The disulphide between Cys36 and Cys95 links the two adjacent strands (L and C) of one  $\beta$ -sheet. A long  $\alpha$ -helix between strands L and M is folded on top of this  $\beta$ -sheet. There is also an N-linked oligosaccharide at Asn32 on this sheet; only one saccharide residue is visible in the electron density.

20        The hydrophobic core between the two sheets is comprised mainly of tryptophans, tyrosines, phenylalanines and leucines. The core is closed off by two  $\beta$ -arches between the two sheets; strands joining B to C and J to K are hydrogen bonded and anti-parallel, an arrangement characteristic of proteins derived from a jellyroll motif. One end of the core, formed by 11 residues at the N-terminus and those in the N and O strands at the C-terminus (Figs. 2, 3), has hydrophobic residues accessible to solvent. The other end of the core is involved in interactions with a neighbouring protomer (see below) and so is inaccessible to solvent.

### 30    *Tertiary fold comparisons*

The similarities of the amino acid sequences of SAP, human and *Limulus* CRP and female hamster protein suggest that they may have similar three-dimensional

- 24 -

structures. Comparative modelling [34] shows that these pentraxins can have equivalent anti-parallel structures with insertions and deletions in the loops between the  $\beta$ -strands and  $\alpha$ -helices (Srinivasan, N., White, H.E. & Blundell, T.L. *unpublished results*).

Fig. 4 shows that most solvent-inaccessible aromatic side-chains are conserved to give compact hydrophobic cores in all members of the family.

The jellyroll topology of the pentraxins is reminiscent of that of the picornavirus coat proteins, which also have pentameric structures. However, pentraxins resemble most closely legume lectins such as concanavalin A [35] and pea lectin [36] (Fig. 2a). In each case the arrangement of strands is identical but the N- and C- termini are in different positions (Fig. 3). In pea lectin the N-terminus is at strand M and the C-terminus at strand L (labelling of the topologically equivalent strands follows those in SAP as shown in Fig. 3). The strands A and M are both hydrogen-bonded to strand L in a similar manner to those in SAP. In the three-dimensional structure of concanavalin A the N-terminus is at strand E and the C-terminus at the end of strand D due to a post-translational cleavage which follows ligation of the true termini between strands L and M [37]. Pea lectin is additionally cleaved at the loop connecting strands I and J.

Alignment of sequences (Fig. 4) on the basis of topologically equivalent features of the three-dimensional structures [29] shows that helices occupy different positions in the pentraxins and legume lectins and that the amino acid sequences of the two families have identities of only ~11%. The two main helices in SAP occur before and after strand L, whereas the helices in the legume lectins occur at the C-terminus of strand J. There is a long insertion between the end of the helix after strand D and the beginning of strand E in the lectins relative to the pentraxins. Strands G, H and I, together with the type IV  $\beta$ -hairpin between H and I, are identical in both SAP and pea lectin. The so-called pentraxin octapeptide signature sequence, H X C X S/T W X S, is in this region, but this is not conserved in the legume lectins.

#### ***Structure of the pentamer and decamer***

The structure of the pentamer is shown in Fig. 2b. The five subunits are arranged in a ring with a hole that is 20Å in diameter and 35Å deep at the centre. The two layers of  $\beta$ -strands in each subunit are in planes normal to the five-fold axis. Strands G, I, J of one protomer interact with strand N and loops between strands A and

- 25 -

B, C and D, G and H, K and L of an adjacent protomer (Fig. 2b). When SAP is overlaid on the pea lectin, strand J does not give as good a fit as other strands. In SAP this strand has moved to provide inter-protomer contacts, with all residues between Pro113 and Leu119 being involved. The subunit interactions consist of hydrogen bonds  
5 between main chain peptide groups, three salt bridges and some hydrophobic contacts, in contrast to other pentameric systems where there are often inter-subunit  $\beta$ -sheets. The surface area of the protomer that is buried on formation of the pentamer is  $410.5\text{\AA}^2$ , comprising 15.4% of the total surface of the protomer. The residues involved in these extensive interactions and which account for the considerable stability of the  
10 SAP pentamer are shown in Fig. 4.

In contrast the SAP decamer is readily dissociated by reducing the pH to 5.5. The simplest explanation for this is that the decamer is stabilised by ionic interactions involving carboxylate and/or imidazole groups. Electron microscopy has clearly shown that the SAP pentamers are packed face-to-face [38] and it seems probable that the  
15 faces in contact are those carrying the  $\alpha$ -helix since we show (see below) that the calcium-dependent ligand-binding sites are on the other face and such binding is exhibited by the decamer. Furthermore adjacent sites are accessible to chymotryptic cleavage in the decamer in the absence of calcium ions. It is not clear which groups are involved in the decamer stabilisation although Glu167, positioned on the helix, is a  
20 likely candidate. A compact decamer can be modelled if the pentamer five-fold axes are in line but the subunits are out of step, allowing the helices from one layer to pack between those of the opposite layer. Structure analysis of a crystal form produced at neutral pH with ten protomers in the asymmetric unit is in progress.

The models of CRP and female hamster protein demonstrate that the pentamers  
25 can have very similar inter-subunit interactions. CRP of the invertebrate *Limulus polyphemus* is hexameric [39] and we have also been able to construct this arrangement of protomers by operating with a six-fold axis placed slightly further from the subunit than the five-fold axis of SAP.

### 30 *Calcium binding site*

In serum amyloid P component we have identified two large spheres of density which are too heavy to be oxygen atoms and are in positions that imply the presence of

- 26 -

calcium ions, between 4.0Å and 4.3Å apart in the five subunits and bridged by a common side-chains. Calcium (1) is coordinated to the side chains of Asp58, Asn59, Glu136, Asp138 and the main-chain carbonyl of Gln137 (Fig. 5a). Unlike many calcium-binding sites in proteins, such as parvalbumin, the coordinating residues come  
5 from different parts of the sequence. This is achieved by a distortion at the start of strand E carrying residues Asp58 and Asn59 and the region containing Glu136 and Asp138 looping over towards calcium (1) (Fig. 5a). The calcium ligation is likely to be an important local structural determinant. The seventh coordination site is occupied by a ligand that has the appearance of an acetate ion from the crystallisation buffer in  
10 protomers 1, 2, 4 and 5, but in protomer 3 this position is filled by the side-chain of Glu167 of an adjacent molecule in the crystal lattice. Glu136, Asp138 and the acetate/lattice contact form a bridge to a second, more loosely bound calcium ion (2). The coordination of calcium (2) is completed by Gln148 and two water molecules. In a cross-phase difference Fourier of cerium sulphate soaked crystals, we find that  
15 calcium (2) is displaced by a cerium ion. Calcium (2) is also removed when the crystals are soaked in calcium free buffers. These observations are consistent with the more solvent accessible position and fewer protein ligands of calcium (2).

Residues which provide ligands to the calcium ions are conserved in all SAPs but although Asp58 is found in hamster SAP, human CRP and *Limulus* CRP it varies in  
20 other CRPs. Nevertheless, the general organisation of the site is probably retained.

However, the disposition of these groups on surface loops where sequence differences accumulate could explain the considerable change in calcium affinity between CRP and SAP. Furthermore, in CRP there is evidence that both calciums bind with the same affinity at neutral pH [40] whereas in SAP our results show that site  
25 calcium (2) has fewer protein ligands and can be preferentially unloaded. The tighter calcium binding and equivalence of the sites in CRP could also be due to the substitution of Asp145 in SAP by glutamate in CRP. The longer side-chain in CRP would permit a full complement of protein ligands to calcium site (2).

The existence of two metal ions bridged by protein ligands is reminiscent of  
30 concanavalin A. However, although the metal binding sites in the legume lectins are on the same face of the protein, they are at a different position between strands E and F compared to D and E on SAP. There are no ligands of the two calciums that are

- 27 -

topologically equivalent to those for the calcium and the manganese of the lectins. Thus, although there is evidence for divergent evolution of the protein folds of the plant lectins and the pentraxins, this is not supported by a conservation of similar metal binding sites.

5

### *Ligand binding*

SAP binds to methyl 4,6-O-(1-carboxyethylidene)- $\beta$ -D-galactopyranoside (MO $\beta$ DG) which is not recognised by CRP. Fig. 1b shows the electron density for MO $\beta$ DG complexed with SAP. The sugar derivative binds directly through the acidic group to the two calcium ions in a similar way to the acetate which it replaces. The other interactions include two hydrogen bonds formed between the 4,6 oxygen atoms of the ring and the amide nitrogen atoms of Gln148 and Asn59 respectively, each of which bind to the calcium ions through their amide oxygens (Fig. 5b). Thus the role of calcium is not to bind the galactopyranoside ring directly but rather to mediate its binding by orienting side-chain amides in a way that resembles saccharide binding in lectins. There is only one hydrogen bond to the galactopyranoside ring (Fig. 5b). Thus it is the methyl 4,6-O-(1-carboxyethylidene) ring that forms the main interactions with the protein, explaining why neither the non-cyclic acetal of MO $\beta$ DG nor the simple monosaccharides bind [3,10,26]. The R-isomer bridge methyl group points into a hydrophobic pocket formed by Leu62, Tyr64 and Tyr74. The differences in the hydrophobic pocket and the ligand distribution at the calciums in CRP may explain the poor binding to MO $\beta$ DG. It is probable that this site is involved in binding to amyloid fibrils.

The highest affinity interaction of human CRP is its calcium-dependent binding to phosphocholine (PC). Studies carried out on human CRP [41,42] have implicated amino acid residues 50-60 in the ability to bind PC while more recent mutagenesis experiments [43] have identified Lys55 and Arg56 as key residues. The native SAP structure shows that Asp58 and Asn59 from this loop are involved in coordinating one of the two calcium ions. Human SAP, in contrast, does not bind to PC although in common with CRP it does bind to phosphoethanolamine (PE). The electron density maps for SAP co-crystallised with PE (Fig. 1c) show a major site in all subunits, which coincides with that which binds acetate ions and MO $\beta$ DG and indicates a direct

- 28 -

interaction between the phosphate group and both calcium ions. In contrast to MO $\beta$ DG this interaction with PE displaces Glu167 from its intermolecular interaction with the calciums of protomer 3, explaining the observed disturbance of crystal packing.

Binding of MO $\beta$ DG or PE in the common site probably stabilises the whole calcium  
5 binding region including Asn59 which binds MO $\beta$ DG and calcium and Asp58 which binds calcium. Both PE and PC probably bind at the calcium in CRP.

SAP rapidly aggregates in neutral solutions in the presence of calcium ions presumably due to intermolecular interactions involving the surface of the decamer with the exposed calcium binding site. This is consistent with the observation that this  
10 interaction can be inhibited by MO $\beta$ DG [44] and PE (unpublished observations). Similarly they compete for the calcium site with Glu167 which is an important lattice contact in the pentamer crystals.

SAP also binds polyanions such as heparan sulphate, dermatan sulphate [7] and DNA [4] in the presence of calcium. It has been suggested that the DNA interaction  
15 involves a decapeptide around Arg120, with some resemblance to certain histone sequences and for which a helical structure was proposed [45]. However, in human SAP this region is not helical and other SAPs do not have arginine at this position. Nevertheless it does have affinity for multivalent anions, as demonstrated by the binding of phosphotungstate at this site in the heavy atom isomorphous derivative (see Table 1).  
20 There are several basic regions in SAP, for example Arg120, Arg77, His78, Lys79 and Arg57, which are on the same surface as the calcium and PE binding sites. It seems more likely that the phosphate backbone of DNA and the sulphated polysaccharides bind both at the calciums and at the basic sites, possibly on more than one subunit simultaneously. These extensive interactions probably account for the ability of SAP to  
25 displace from DNA the H1-type histones in chromatin [5]. The sequence differences in the basic regions and in the calcium binding region could explain the variable affinity for DNA shown by different pentraxins. Human CRP, for instance, only binds DNA at low, non-physiological ionic strength. PE and MO $\beta$ DG both enhance the binding of DNA by SAP and compete with the interaction at high concentration [unpublished  
30 observations]. Similar effects are observed for SAP binding to immobilised PE [unpublished observations]. As we can find no evidence for a second binding site for PE or MO $\beta$ DG in the present experimental conditions, these effects must be mediated

- 29 -

through inter-subunit interactions.

Ligands for SAP, such as PE in phosphatidylethanolamine and MO $\beta$ DG-like sugars [46], are common in microorganisms. In this respect SAP resembles CRP [13] and the mammalian C-type lectin, mannose-binding protein [47], which both recognise  
5 widely distributed microbial epitopes and are involved in host defence against infection. SAP could act either directly or via complement, since aggregated or complexed SAP [5,48] like mannose-binding protein [47] and CRP [13], can activate the classical complement pathway.

#### 10 *Proteinase-resistance of pentraxins and the treatment of amyloidosis*

SAP and CRP are both remarkably resistant to proteolytic degradation in the presence of calcium. In contrast, in the absence of calcium both are cleaved by some enzymes, particularly  $\alpha$ -chymotrypsin and pronase [40,49]. Although this cleavage does not cause fragmentation of either the whole molecule or of the individual subunits under  
15 non-denaturing conditions, it does cause loss of calcium-binding activity by the pentraxins and abolishes their capacity for calcium-dependent ligand binding. It is, therefore, of interest that the major site of cleavage of SAP is between residues 144 and 145 whilst in CRP it is between residues 146-147 (pronase) or 145-146 (Nagarse protease). This is part of a loop that is held in place by calcium ligation, and which, in  
20 the calcium-free form, may be only loosely associated with the body of the protein and, therefore, susceptible to proteolysis. Most loops of SAP are held close to the body of the pentamer and this makes them less easily accessible to the active sites of proteolytic enzymes.

Resistance to proteinase digestion is likely to be an important aspect of the  
25 normal function of SAP, and may also contribute to the persistence of amyloid deposits. The SAP normally associated with the glomerular basement membrane and the surface of elastic fibre microfibrils [8,9] may protect these extracellular matrix constituents from inappropriate degradation. On the other hand, amyloid fibrils are abnormal extracellular structures which should be recognised and degraded, but which nevertheless persist *in*  
30 *vivo*. In this pathological situation the binding of SAP to amyloid fibrils may be responsible. Protection could result simply from coating by SAP, which is completely unaltered with respect to its normal circulating form [11], and which would, therefore,

- 30 -

not be expected to trigger macrophage activation or phagocytosis. However, the proteinase resistance of SAP itself may be a significant factor. Availability of the complete high resolution structure of SAP and its ligand-binding site now offer the opportunity for direct modelling of competitive inhibitors of SAP binding and for engineering binding site homologues, either of which could be used as drugs to displace SAP from amyloid deposits *in vivo*. This opens up new avenues for treatment of amyloidosis, enabling the body to mobilise and degrade the fibrils which may otherwise be inappropriately protected by SAP.

Table 1 below relates to the method used in determining the three-dimensional structure of SAP:

Legend for TABLE 1

Heavy atom derivatives used for multiple isomorphous replacement and data collection statistics are shown in Table 1. Native data were collected from one crystal on a Hilger-Watts 290 4-circle diffractometer with  $R_{\text{sym}} = 4.5\%$  for 4112 independent reflections to  $5.6\text{\AA}$ . High resolution native data were also collected on film at the Synchrotron Radiation Source at Daresbury Laboratory ( $\lambda = 1.468\text{\AA}$ ) using three crystals ( $R = 7.7\%$ ) for 78951 unique reflections to  $2.02\text{\AA}$ . The final merged data set comprised low resolution data from the diffractometer and high resolution data from the synchrotron. The major heavy atom sites were determined from inspection of difference Patterson functions and cross-phase difference Fouriers. A multiple isomorphous replacement (MIR) map was calculated, solvent flattened and averaged. Phases from both maps were used in cross-phase difference Fouriers to determine those minor sites related by the 5-fold axis to the major sites. All sites were initially refined with VECREF (I.J. Tickle) to eliminate spurious sites and then with PHARE. A final MIR map was calculated to  $2.8\text{\AA}$  and the phasing analysis gave a figure of merit of 0.61. This map was solvent flattened [32], phases calculated and recombined with the MIR phases to give a combined figure of merit of 0.85. The solvent flattened map was then averaged using PSAVER (I.J. Tickle) and the envelope determined in the solvent flattening. The polypeptide of the  $\beta$ -sheet and helix were well defined. Derivative data were also scaled to native data collected from three crystals on a FAST area detector mounted on a  $\text{CuK}\alpha$  microfocus tube (800W) ( $R_{\text{sym}} = 10.0\%$  for 30996 independent



- 31 -

reflections to 2.8Å). Heavy atom sites were determined independently from those in Table 1 and were refined using MLPHARE. The resulting electron density map was solvent flattened and averaged using the programs supplied with O release 5.7. The map was similar to that used for the refinement. Problems in obtaining an interpretable map arose because not all substituted sites related by the non-crystallographic symmetry were present on early cross-phase difference Fourier's due to poor phasing from the derivatives available at the time. Two of the three derivatives with the highest phasing power were the last to be collected. These extra derivatives allowed minor sites related to the major sites by the 5-fold axis to be determined in the early derivatives as well as multiple occupancy in some sites previously thought to be singly occupied. For example the dominant thorium nitrate derivative formed a complex with eleven thorium sites comprising two octahedra, each with edges of approximately 4Å and sharing an apex.

The direction of the 5-fold axis was determined from a self-rotation function [15], and the approximate position of the molecule on this axis was found by positioning a pentagonal prism in a low resolution MIR map. A six-dimensional search (3 rotations and 3 translations) for a best correlation in the map for a given rotational operation was performed using LOCROT (I.J. Tickle). The parameters were then refined with the density correlation programs of Bricogne [33].

One averaged subunit of the electron density map obtained from the solvent flattening was displayed in FRODO [50] on an Evans and Sutherland PS390. The sequence could be assigned from the position of the disulphide bridge and the putative calcium binding site for all residues in the sheets and helix. The resolution was extended with simulated annealing using non-crystallographic restraints in XPLOR [51] and rebuilding into electron density maps (coefficients 2Fo-Fc, Fo-Fc) calculated from phases that had been combined with the MIR phases until all residues had been inserted. The resolution was then extended to 2Å and 10 calcium ions, 4 acetate ions and 879 water molecules were added. Least squares refinement in RESTRAIN [52] gave a crystallographic R-factor of 0.179 for all 78910 reflections in the resolution range 8-2Å. The r.m.s. deviations from stereochemical ideality are 0.017Å for bond distances and 3.45° for bond angles. The average isotropic B values are 22.9Å<sup>2</sup> for protein and 37.7Å<sup>2</sup> for solvent molecules. There were no residues in the disallowed

- 32 -

region of a Ramachandran plot [53]. The CCP4 suite of programs (SERC Daresbury) has been used for all crystallographic calculations, except the structural refinement.

$$\text{Merging R factor} \quad \frac{\sum_{hkl} \sum_{i=1}^n |I(hkl)_i - \bar{I}(hkl)|}{\sum_{hkl} \sum_{i=1}^n I(hkl)_i}$$

$$\text{Isomorphous R factor} \quad \frac{\sum_{hkl} |F_{deriv}(hkl) - F_{nat}(hkl)|}{\sum_{hkl} |F_{nat}(hkl)|}$$

$$\text{Phasing power} \quad [\sum_{hkl} F_{heavy}^2(hkl) / \sum_{hkl} e^2(hkl)]^{1/2}$$

TABLE 1 Structure determination of SAP

DERIVATIVE	K <sub>2</sub> PTI <sub>6</sub>	Na <sub>3</sub> PO <sub>4</sub> ·12WO <sub>3</sub>	Th(NO <sub>3</sub> ) <sub>4</sub>	Th(NO <sub>3</sub> ) <sub>4</sub>	Ce(SO <sub>4</sub> ) <sub>2</sub>	K <sub>2</sub> AuCl <sub>4</sub>	UO <sub>2</sub> SO <sub>4</sub>	AgNO <sub>3</sub>	Na <sub>2</sub> WO <sub>4</sub>
CONCENTRATION (mM)	5.0	5.0	4.5	4.5	17.0	2.5	25.0	5.0	11.0
SOAKING TIME (h) at 20°C	24.0	60.0	28.0	28.0	48.0	1.0	24.0	24.0	19.0 (4°C)
COLLECTION DEVICE	F	F	F	F	F	F	X	I	D
RESOLUTION (Å)	3.5	3.5	4.1	2.8	3.0	3.5	3.2	3.4	6.0
MERGING R FACTOR	0.084	0.069	0.062	0.049	0.101	0.110	0.045	0.118	0.075
ISOMORPHOUS R FACTOR	0.317	0.237	0.203	0.278	0.222	0.310	0.251	0.165	0.225
% COMPLETE	88.3	80.3	91.7	85.8	76.7	71.1	81.0	93.4	97.1
NUMBER OF SITES	28	21	17	14	27	22	22	26	-
PHASING POWER	1.00	1.15	1.43	2.02 (4.1-2.8Å)	1.02	1.55	1.29	1.04	-

D, Enraf-Nonius CAD-4 diffractometer mounted on a 1500W sealed tube; F, Enraf-Nonius FAST area-detector mounted on a Cukα microfocus tube (800W); X, Siemens Xentronics area-detector mounted on a Siemens XP18 generator; I, MAR research imaging plate mounted on a Siemens XP18 generator.

- 34 -

The following non-limiting Examples illustrate the invention.

#### EXAMPLE 1

##### 5 Protocol for testing for inhibition of SAP binding to amyloid fibrils

- Amyloid fibrils are isolated from the organs, such as the spleen, obtained post mortem from patients with amyloidosis of AA or AL type, using the water extraction method of Pras et al [55]. This method is modified in that the initial saline homogenizations are
- 10 conducted using Tris buffered saline containing 10 mM EDTA to ensure complete dissociation of all endogenous SAP [56]. The fibril-rich water extract is mixed with Tris buffered saline containing calcium chloride to bring the final salt concentration to 138 mM NaCl, 10 mM Tris, 2mM CaCl<sub>2</sub>, pH 8.0, and this is then centrifuged at 1500 g for 5 minutes to sediment the fibrils. These are then resuspended in Tris saline calcium
- 15 buffer, pH 8.0, at the same concentration as above (TC buffer), so as to provide a suitable suspension, for example,  $A_{280}=0.255$ ,  $A_{320}=0.132$ , and this is stored at 4°C. Highly purified human SAP, isolated as described previously [31, 57] is radioiodinated with <sup>125</sup>I, as previously described [58] to a specific activity of about 0.1  $\mu$ C/ $\mu$ g and is diluted immediately before use to about 70  $\mu$ g/ml in TC containing 4% w/v bovine
- 20 serum albumin. Agents to be tested are dissolved at a concentration of about 10 mM in TC, or in 1:10 DMSO in water or TC. If they are active in inhibiting SAP binding they are tested at a range of lower concentrations to determine the minimal inhibitory dose.
- 25 For the assay itself, 10  $\mu$ l of labelled SAP is mixed with 50  $\mu$ l of amyloid fibril suspension and 40  $\mu$ l of the test substance and incubated, with mixing, for 60 minutes at room temperature. Controls include SAP alone without fibrils, SAP and fibrils without any potential inhibitor, SAP and fibrils in the presence of EDTA to prevent any binding of SAP, and SAP plus inhibitor without fibrils to control for non-specific
- 30 effects, such as denaturation, induced by test substances. After the incubation the fibrils with bound SAP are separated from unbound SAP either by centrifugation at 1500 g for 5 minutes, or by filtration in the Millipore Multiscreen Assay system using 0.22  $\mu$

- 35 -

Durapore low protein binding multiwell filter plates. The fibrils are washed with TC containing 1% w/v BSA and the radioactive SAP bound is measured.

Typically about 75% of the activity offered is bound in the absence of any inhibitor;  
 5 none is bound in the presence of EDTA, and in the absence of fibrils less than 5% of the activity sediments on its own.

MO $\beta$ DG, at concentrations above about 2 mM in the final incubation mixture, reduces binding to background levels. An example of a typical set of results is set out in Table  
 10 2 below:

**TABLE 2**

**Inhibition by MO $\beta$ DG of SAP binding to amyloid fibrils**

AA type amyloid fibrils (A <sub>280</sub> )	MO $\beta$ DG (mM)	SAP binding (%)
0.4	0	82
0.1	0	63
0.025	0	13
0.1	30	2
0.1	20	2
0.1	10	5
0.1	5	17
0.1	1	46

In the presence of EDTA, or in the absence of fibrils, apparent SAP binding was 1%.

- 36 -

## EXAMPLE 2

### Protection by SAP against digestion of amyloid fibrils in vitro and abrogation of that protection by MOBDG

5

The method used is as follows:

#### Amyloid fibrils

Any type of amyloid fibril may be used in the following protocol, for example, amyloid  
10 fibrils may be obtained ex vivo or Alzheimer's disease  $\beta$ -protein may be produced synthetically.

Alzheimer's disease  $\beta$ -protein, prepared as a synthetic peptide containing residues 1-40  
was obtained from California Peptide Research, and was dissolved in pure water at 4  
15 mg/ml, that is 1 mM. Some was kept at 4°C ("fresh") and some was aged by incubation at 37°C for 7 days. It is known that fibrils form very slowly in the cold but that "ageing" is associated with marked amyloid fibril formation, and this was confirmed in the present case by Congo red staining and by direct electron microscopy.

#### 20 Methods and results

(a)  $\beta$ -protein solutions obtained as described above were diluted to 0.2 mg/ml in TC immediately before use. Highly purified human SAP in solution in 138 mM NaCl, 10 mM Tris, pH 8.0 (TN) was diluted in TN to 0.1 mg/ml, 0.5 mg/ml and 2.5 mg/ml  
Pronase from S. griseus was obtained from Boehringer Mannheim and was freshly  
25 prepared at 0.04 and 0.004 mg/ml in TC just before use.

Aliquots, 50  $\mu$ l, of aged or fresh  $\beta$ -protein were mixed with 20  $\mu$ l volumes of TN alone or SAP at the different concentrations shown in Figure 6 and with 5  $\mu$ l of 10 mM  $\text{CaCl}_2$ , and then incubated with shaking at 37°C for 1 hour. TC alone or pronase in TC  
30 at 0.04 or 0.004 mg/ml were added in a volume of 25  $\mu$ l and incubation continued for a further 1 hour at 37°C. Digestion was then stopped by addition of an equal volume of reducing SDS-PAGE sample buffer (20 mM Tris pH 8.0, 2 mM EDTA, 5% w/v SDS,

- 37 -

10% w/v 2-mercaptoethanol, 0.05% w/v bromophenol blue, 20% w/v glycerol) and boiling for 10 minutes. These samples were finally analysed in reduced SDS homogeneous 15% PAGE, stained with Brilliant blue R350. The proportion of the  $\beta$ -protein present in each track was estimated by scanning densitometry with reference to the no pronase control which was taken as 100%. The proportion digested was calculated by subtraction and plotted against the SAP concentration.

The results obtained are shown in Figure 6.

- 10 (b) AA amyloid fibrils obtained ex vivo were incubated for 6 hours at 37°C with trypsin or chymotrypsin at a substrate:enzyme ratio of 10:1 in the presence or absence of SAP and with or without MOBDG, according to the general protocol given above. The incubation mixtures were then analysed by Coomassie blue stained SDS-PAGE with quantification of the AA protein band. Intensity of this band after incubation without
- 15 trypsin was taken as 100%. The results are presented in Table 3 below.

**TABLE 3**

**Effect of SAP on proteinase digestion of AA amyloid fibrils**

<i>Proteinase</i>	<i>SAP (<math>\mu\text{g/ml}</math>)</i>	<i>MO<math>\beta</math>DG (mM)</i>	<i>% AA protein remaining</i>
-	-	-	100
Trypsin	-	-	5
Trypsin	10 $\mu\text{g/ml}$	-	20
Trypsin	50 $\mu\text{g/ml}$	-	50
Trypsin	50 $\mu\text{g/ml}$	1 mM	5
Chymotrypsin	-	-	10
Chymotrypsin	10 $\mu\text{g/ml}$	-	20
Chymotrypsin	50 $\mu\text{g/ml}$	-	60
Chymotrypsin	50 $\mu\text{g/ml}$	1 mM	10

- 38 -

(c) In a further variant, the amyloid fibrils used (ex vivo or synthetic) may be labelled with a radioisotope, for example, radioiodine and digestion then monitored by measurement of release of trichloric acid-soluble radioactivity rather than by SDS-PAGE.

AA amyloid fibrils were oxidatively labelled with  $^{125}\text{I}$ . The labelled fibrils were incubated with SAP and pronase following the general protocol set out above, except that the incubation was carried out for 1, 4 and 24 hours. The trichloroacetic acid-soluble  $^{125}\text{I}$  released was determined. Figures 7 and 8 show the results obtained at various SAP concentrations.

(d) Abrogation of protection by MO $\beta$ DG:  $\beta$ -protein fibrils at 100  $\mu\text{g/ml}$  were incubated for 1 hour at 37°C with pronase at 1  $\mu\text{g/ml}$ , in the presence or absence of SAP and with or without different concentrations of MO $\beta$ DG. The extent of digestion of the  $\beta$ -protein was then estimated by SDS-PAGE analysis. The results, which demonstrate clearly the abrogation by MO $\beta$ DG of the protection afforded by SAP against proteinase digestion of amyloid fibrils, are presented in Table 4 below and in Figure 9.

20

**TABLE 4**

**Abrogation by MO $\beta$ DG of the protection against proteinase digestion of Alzheimer's disease  $\beta$ -protein fibrils conferred by serum amyloid P component**

SAP concentration ( $\mu\text{g/ml}$ )	MO $\beta$ DG concentration (mM)	Digestion of $\beta$ -protein (%)
0	0	95
10	0	60
10	1.3	75
10	6.7	85
10	33.3	90



- 39 -

EXAMPLE 3Capacity of mice deprived of SAP to develop AA amyloidosis in an accelerated model of amyloidogenesis

5

Amyloid was induced rapidly in mice by intravenous injection of an extract of amyloidotic spleen (so-called amyloid enhancing factor) together with a single profound acute phase stimulus (subcutaneous injection of silver nitrate) [59] on day 0. Group 1 had no other treatment; groups 2 and 3 received, respectively, sheep anti-mouse SAP and sheep anti-mouse C3 antibodies on day -1, day 0 and day 1. All animals were  
10 killed on day 2 and the presence of amyloid deposits sought histologically by Congo red staining.

All control animals developed appreciable splenic amyloidosis within 48 hours. In  
15 contrast all mice in which circulating SAP had been completely removed by administration of adequate doses of sheep anti-mouse SAP antiserum failed to develop any detectable amyloid deposits. A further control group which received sheep antiserum to mouse C3, an unrelated serum protein not involved in amyloidosis, almost all developed amyloid. The results are set out in Table 5 below.

20

**TABLE 5****Effect of SAP depletion on induction of AA amyloidosis in mice**

<i>Group</i>	<i>Treatment</i>	<i>Number of animals</i>	<i>Number developing amyloid</i>	<i>(%)</i>
1	None	10	10	100
2	Anti-mouse SAP antibody	17	0	0
3	Anti-mouse C3 antibody	9	8	89

- 40 -

These preliminary studies confirm that the mechanism of action of the anti-mouse SAP is indeed via SAP depletion, and show that SAP is required for amyloidogenesis. This may reflect the need for SAP to protect newly formed fibrils from proteolysis, as  
5 indicated by the work on protection of fibrils from proteolysis described above, or there may be a direct role for SAP in amyloid fibrillogenesis which has not previously been suspected. In any case the results support our in vitro results and focus attention on inhibition of SAP binding to amyloid fibrils as a most attractive target for therapeutic attack in all forms of amyloidosis. A suitable inhibitory agent will act prophylactically  
10 to prevent development of the common age-associated diseases caused by amyloid deposition, especially AD and type II (maturity onset) diabetes mellitus.

### References

1. Coria, F., *et al.* *Lab. Invest.* **58**, 454-458 (1988).
2. Pepys, M.B., Dyck, R.F., de Beer, F.C., Skinner, M. & Cohen, A.S. *Clin. exp. Immunol.* **38**, 284-293 (1979).
- 5 3. Hind, C.R.K., Collins, P.M., Caspi, D., Baltz, M.L. & Pepys, M.B. *Lancet ii*, 376-378 (1984).
4. Pepys, M.B. & Butler, P.J.G. *Biochem. Biophys. Res. Comm.* **148**, 308-313 (1987).
5. Butler, P.J.G., Tennent, G.A. & Pepys, M.B. *J. exp. Med.* **172**, 13-18 (1990).
- 10 6. de Beer, F.C., Baltz, M.L., Holford, S., Feinstein, A. & Pepys, M.B. *J. exp. Med.* **154**, 1134-1149 (1981).
7. Hamazaki, H. *J. biol. Chem.* **262**, 1456-1460 (1987).
8. Breathnach, S.M., *et al.* *Nature* **293**, 652-654 (1981).
9. Dyck, R.F., *et al.* *J. exp. Med.* **152**, 1162-1174 (1980).
- 15 10. Hind, C.R.K., *et al.* *J. exp. Med.* **159**, 1058-1069 (1984).
11. Pepys, M.B., *et al.* *Proc. 41st ASMS Conference on Mass Spectrometry and Allied Topics*, San Francisco, California, May 30-June 4, 1993 (in press).
12. Pepys, M.B., *et al.* *Nature* **273**, 168-170 (1978).
13. Pepys, M.B. & Baltz, M.L. *Adv. Immun.* **34**, 141-212 (1983).
- 20 14. Hawkins, P.N., Lavender, P.J. & Pepys, M.B. *New Engl. J. Med.* **323**, 508-513 (1990).
15. Wood, S.P., *et al.* *J. molec. Biol.* **202**, 169-173 (1988).
16. Goodford, P.J. *J. Med. Chem.* **28**, 849-857 (1985).
17. Grootenhuis, P.D.J., Van Geerestein, V.J., Haasnoot, C.A.G. & Karplus, M. *Bull. Soc. Chim. Belg.* **101**, 661 (1992).
- 25 18. Lawrence, M.C. & Davis, P.C. *Proteins* **12**, 31-41 (1992).
19. Rotstein, S.H. & Murcko, M.A. *J. Comput. Aided Molec. Des.* **7**, 23-43 (1993).
20. Blundell, T.L., Gardner, S.P., Hayes, F., Howlin, B. & Sutcliffe, M. *Eur. J. Biochem.* **172**, 513-520 (1988).
- 30 21. Hawkins, P.N., *et al.* *Q. J. Med.* **86**, 365-374 (1993).
22. Hawkins, P.N., *et al.* *Arthritis Rheum.* **36**, 842-851 (1993).
23. Holmgren, G., *et al.* *Lancet* **341**, 1113-1116 (1993).

24. Hawkins, P.N., *et al.* In: *Amyloid and Amyloidosis 1993* (Kisilevsky, R., *et al.*, eds.), Parthenon Publishing, Pearl River, New York (in press).
25. Hawkins, P.N., *et al.* In: *Amyloid and Amyloidosis 1993* (Kisilevsky, R., *et al.*, eds.), Parthenon Publishing, Pearl River, New York (in press).
- 5 26. Evans, S.V. *J. molec. Graphics* **11**, 134-138 (1993).
27. Hutchinson, E.G. & Thornton, J.M. *Proteins* **8**, 203-212 (1990).
28. Kabsch, W. & Sander, C. *Biopolymers* **22**, 2577-2637 (1983).
29. Sali, A. & Blundell, T.L. *J. mol. Biol.* **212**, 403-442 (1990).
30. Overington, J.P., Johnson, M.S., Sali, A. & Blundell, T.L. *Proc. roy. Soc. London ser. B* **241**, 146-152 (1990).
- 10 31. Hawkins, P.N., Tennent, G.A., Woo, P. & Pepys, M.B. *Clin. exp. Immunol.* **84**, 308-316 (1991).
32. Wang, B.C. *Meth. Enzymol.* **115**, 90-112 (1985).
33. Bricogne, G. *Acta Cryst.* **A32**, 832-847 (1976).
- 15 34. Sali, A., Overington, J.P., Johnson, M.S. & Blundell, T.L. *Trends Biochem. Sci.* **15**, 235-240 (1990).
35. Hardman, K.D. & Ainsworth, C.F. *Biochemistry* **11**, 4910-4919 (1972).
36. Einspahr, H., Parks, E.H., Suguna, K., Subramanian, E. & Suddath, F.L. *J. biol. Chem.* **261**, 16518-16527 (1986).
- 20 37. Carrington, D.M., Auffret, A. & Hanke, D.E. *Nature* **313**, 64-67 (1985).
38. Pepys, M.B., *et al.* *Lancet* **i**, 1029-1031 (1977).
39. Tennent, G.A., *et al.* *Eur. J. Biochem.* **214**, 91-97 (1993).
40. Kinoshita, C.M., *et al.* *Biochemistry* **28**, 9840-9848 (1989).
41. Swanson, S.J. & Mortenson, R.F. *Molec. Immun.* **27**, 679-687 (1992).
- 25 42. Liu, T.-Y. *et al.* *J. Protein Chem.* **6**, 263-272 (1987).
43. Agrawal, A., Xu, Y., Ansardi, D., Macon, K.J. & Volanakis, J.E. *J. biol. Chem.* **267**, 25352-25358 (1992).
44. Hind, C.R.K., Collins, P.M. & Pepys, M.B. *Biochim. Biophys. Acta* **802**, 148-150 (1984).
- 30 45. Turnell, W.G., Satchwell, S.C. & Travers, A.A. *FEBS Lett.* **232**, 263-268 (1988).
46. Hind, C.R.K., Collins, P.M., Baltz, M.L. & Pepys, M.B. *Biochem. J.* **225**, 107-111 (1985).

- 43 -

47. Hartshorn, K.L., et al. *J. clin. Invest.* 91, 1414-1420 (1993).
48. Ying, S.C., Gewurz, A.T., Jiang, H. & Gewurz, H. *J. Immunol.* 150: 169-176 (1993).
- 5 49. Kinoshita, C.M., et al. *Protein Sci.* 1, 700-709 (1992).
50. Jones, T.A. *J. appl. Cryst.* 11, 272-282 (1978).
51. Brunger, A.T., Karplus, M. & Petsko, G.A. *Acta Cryst.* A45, 50-61 (1989).
52. Haneef, I., Moss, D.S., Stanford, M.J. & Borkakoti, N. *Acta Cryst.* A41, 426-433 (1985).
- 10 53. Ramachandran, G.N., Ramakrishnan, C. & Sasisekharan, V. *J. molec. Biol.* 1, 95-99 (1963).
54. Hardy, J. *Nature Genetics* 1, 233-234 (1992)
55. Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A., & Franklin, E.C. *J. Clin. Invest.* 47, 924-933 (1968)
- 15 56. Nelson, S.R., Lyon, M., Gallagher, J.T., Johnson, E.A., & Pepys, M.B. *Biochem. J.* 275, 67-73 (1991)
57. de Beer, F.C. and Pepys, M.B. *J. Immunol. Methods* 50, 17-31 (1982)
- 20 58. Hawkins, P.N., Wootton, R. and Pepys, M.B. *J. Clin. Invest.* 86, 1862-1869 (1990)
59. Balz, M.L., Caspi, D., Hind, C.R.K., Feinstein, A. & Pepys, M.B. *Amyloidosis* (1990) Glenner et al., Eds., Plenum Press, New York, pp 115-121.
- 25 60. Alper, J. *Science* 264, 1399-1402 (1994)
61. Kohler & Milstein *Nature* 256, 495-497 (1975)
62. Pepys, M.B., Dash, A.C., Fielder, A.H.L. and Mirjah, D.D. *Immunology* 33, 491-499 (1977)
63. Pepys, M.B., Baltz, M., Gomer, K., Davies, A.J.S. and Doenhoff, M. *Nature* 278, 259-261 (1979)
- 30

- 44 -

## CLAIMS:

1. A method of producing a molecule having a structural relationship to a protein molecule, the method comprising  
(i) using the three-dimensional structure of the protein as the  
5 basis for the design of the molecule, and then (ii) synthesising the molecule thus-designed, characterised in that the protein is serum amyloid P component and the molecule produced binds to the amyloid fibril binding site, or is an analogue or homologue of the amyloid fibril binding site or is  
10 capable of binding with high affinity to amyloid fibrils.
2. A method for the production of a molecule that inhibits the binding of serum amyloid P component to amyloid fibrils, or is an analogue or homologue of the amyloid fibril binding  
15 site or is capable of binding with high affinity to amyloid fibrils which comprises carrying out computer-aided molecular design using the three-dimensional structure of serum amyloid P component, synthesising the molecules thus designed and testing the molecules (i) for the ability to inhibit binding  
20 of serum amyloid P component to amyloid fibrils and/or (ii) for the ability to bind to amyloid fibrils.
3. A method suitable for use in the treatment, prophylaxis or diagnosis of amyloidosis, which comprises determining the  
25 ability of a candidate molecule to inhibit binding of serum amyloid P component to amyloid fibrils in vitro or to bind amyloid fibrils in vitro.
4. A method as claimed in claim 3, wherein a candidate  
30 molecule is obtainable by carrying out computer-aided molecular design using the three dimensional structure of serum amyloid P component, in particular the three-dimensional structure at and/or around the calcium binding site and then synthesising the molecule so-designed.
- 35 5. A method as claimed in claim 4, wherein a candidate molecule is a modified version of a molecule designed by

- 45 -

computer-aided molecular design.

6. A method as claimed in any one of claims 1, 2, 4 and 5,  
wherein the three-dimensional structure at and/or around the  
5 calcium binding site is the basis for the design of the  
molecule.

7. A method as claimed in any one of claims 1, 2, 4, 5 and 6,  
wherein one or more of the following are used in the design of  
10 the molecule: the final refined electron density of serum  
amyloid P component described herein and illustrated in Figure  
1; the ribbon drawing described herein and illustrated in  
Figure 3; hydrogen bonding diagrams set out in Figure 3; one  
or more of the calcium and ligand binding sites described  
15 herein and illustrated in Figure 4; and the three-dimensional  
structure at and/or around the calcium binding site described  
herein and illustrated in Figures 5a and 5b.

8. A method as claimed in any one of claims 1, 2 and 4 to 7,  
20 wherein the structure of MOBDG and/or its binding to the  
calcium binding site is used as the basis of the design of a  
candidate molecule for that site.

9. A method as claimed in claim 8, wherein a candidate  
25 inhibitor molecule has more interactions at the binding site  
than does MOBDG.

10. A method as claimed in any one of claims 1, 2 and 4,  
wherein a candidate inhibitor molecule interacts with one or  
30 more of the residues Asp58, Asn59, Glu136, Asp138 and Gln37 of  
human serum amyloid P component or the equivalent residues in  
serum amyloid P component of another species and/or with one  
or more basic residues in the region of those residues.

35 11. A method as claimed in any one of claims 1, 2 and 4,  
wherein a candidate inhibitor molecule forms hydrogen bonds to  
the hydroxyl groups of Tyr64 and Tyr75 of human serum amyloid

- 46 -

P component or the equivalent residues in serum amyloid P component of another species.

12. A molecule that inhibits the binding of serum amyloid P  
5 component to amyloid fibrils, other than 4,6-O-(1-carboxyethylidene)- $\beta$ -D-galactopyranoside (MOBDG) and phosphoethanolamine (PE).

13. A molecule as claimed in claim 12 which interacts with  
10 serum amyloid P component at and/or around the calcium binding site illustrated in Figures 5a and 5b.

14. A molecule as claimed in claim 13 which interacts with one  
or more of the residues Asp58, Asn59, Glu136, Asp138 and Gln37  
15 of human serum amyloid P component or the equivalent residues in serum amyloid P component of another species and/or with one or more basic residues in the region of those residues.

15. A molecule as claimed in claim 13 or claim 14, which has  
20 more interactions at the calcium binding site than does 4,6-O-(1-carboxyethylidene)- $\beta$ -D-galactopyranoside (MOBDG).

16. A molecule as claimed in claim 12, which forms hydrogen  
bonds to the hydroxyl groups of Tyr64 and Tyr75 of human serum  
25 amyloid P component or the equivalent residues in serum amyloid P component of another species.

17. A molecule as claimed in any one of claims 12 to 16, which  
binds with high affinity.

30

18. A molecule as claimed in claim 12, which is a  
physiologically tolerable structural analogue of a serum  
amyloid P component ligand.

35 19. A molecule as claimed in claim 18, wherein the molecule a  
physiologically tolerable structural analogue of MOBDG or of  
phosphoethanolamine.



- 47 -

21. An inhibitor molecule as claimed in any one of claims 12 to 20, or obtainable according to any one of claims 1 to 11, and which is physiologically tolerable.
- 5 22. A pharmaceutical preparation which comprises a molecule as claimed in claim 21, in admixture or conjunction with a pharmaceutically suitable carrier.
23. A molecule as claimed in claim 21, for use as a  
10 medicament.
24. Use of a molecule as claimed in claim 21 for the manufacture of a medicament for the treatment or prophylaxis of amyloidosis, especially Alzheimer's disease.
- 15 25. An in vivo diagnostic imaging agent, which comprises a molecule as claimed in claim 21, which molecule is labelled with a tracer (marker) substance that is detectable in vivo.
- 20 26. An agent as claimed in claim 25, wherein the tracer is a radioisotope of iodine, indium or technetium, or is a magnetic resonance tracer.
27. A molecule as claimed in any one of claims 12 to 21,  
25 linked to a different pharmacologically active substance.
28. An analogue or homologue of the binding site for amyloid fibrils on serum amyloid P component, which binding site analogue is capable of binding amyloid fibrils.
- 30 29. A binding site analogue or homologue as claimed in claim 28, which comprises an analogue or homologue of the calcium binding site of serum amyloid P component illustrated in Figures 5a and 5b, and optionally comprises an analogue or  
35 homologue of structures around the calcium binding site, especially patches of basic residues.
30. A binding site analogue as claimed in claim 28 or claim

- 48 -

Figures 5a and 5b, and optionally comprises an analogue or homologue of structures around the calcium binding site, especially patches of basic residues.

- 5 30. A binding site analogue as claimed in claim 28 or claim 29, which comprises a synthetic or recombinant protein, polypeptide or peptide having a sequence identical or homologous to the corresponding sequence in native human serum amyloid P component.
- 10 31. A binding site analogue as claimed in claim 28 or claim 29, which is a low molecular weight polypeptide.
- 15 32. A binding site analogue or homologue as claimed in any one of claims 28 to 31, wherein the serum amyloid P component is human serum amyloid P component.
- 20 33. A low molecular weight polypeptide or other molecule that has high affinity for amyloid fibrils.
- 25 34. A pharmaceutical preparation which comprises a binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims 1 to 8, or a low molecular weight peptide or other molecule as claimed in claim 33 or obtainable according to any one of claims 1 to 8, in admixture or conjunction with a pharmaceutically suitable carrier.
- 30 35. A binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims 1 to 8, or a low molecular weight peptide or other molecule as claimed in claim 33 or obtainable according to any one of claims 1 to 8, for use as a medicament.
- 35 36. Use of a binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims 1 to 8, or a low molecular weight peptide or other

- 49 -

substance as claimed in claim 33 or obtainable according to any one of claims 1 to 8, for the manufacture of a medicament for the treatment or prophylaxis of amyloidosis, especially Alzheimer's disease and maturity onset diabetes mellitus.

5

37. An in vivo diagnostic imaging agent, which comprises a binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims 1 to 8, or a low molecular weight polypeptide or other molecule  
10 as claimed in claim 33 or obtainable according to any one of claims 1 to 8, which molecule is labelled with a tracer (marker) substance that is detectable in vivo.

38. An agent as claimed in claim 37, wherein the tracer is a  
15 radioisotope of iodine, indium or technetium, or is a magnetic resonance tracer.

39. A binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims  
20 1 to 8, or a low molecular weight polypeptide or other substance as claimed in claim 33 or obtainable according to any one of claims 1 to 8, linked to a different pharmacologically active substance.

40. A method of screening potential therapeutic agents for the  
25 treatment of amyloidosis, which comprises bringing the agent into contact with a binding site analogue or homologue as claimed in any one of claims 28 to 32 or obtainable according to any one of claims 1 to 8, or a low molecular weight  
30 polypeptide or other molecule as claimed in claim 33 or obtainable according to any one of claims 1 to 8, and assessing the resulting interaction.

41. An antibody, antibody fragment or antibody derivative that  
35 interacts selectively with the or with a part of the amyloid fibril binding site of serum amyloid P component.

- 50 -

42. A method of treatment or prophylaxis of amyloidosis, which comprises administering to a subject an effective amount of a molecule as claimed in claim 21, or a binding site analogue as claimed in any one of claims 28 to 32 or obtainable according  
5 to the method of any one of claims 1 to 8, or a low molecular weight polypeptide or other substance as claimed in claim 33 or obtainable according to any one of claims 1 to 8.

43. A method for the in vivo diagnosis of amyloidosis, which  
10 comprises administering to a subject an in vivo diagnostic imaging agent as claimed in claim 37 or claim 38, and carrying out imaging on the subject to detect any resulting uptake of the agent by one or more tissues.

1 / 16




Fig. 1a

RECTIFIED SHEET (RULE 91)




Fig. 1b



Fig.1c




Fig. 2a






Fig. 2b





Fig.3 ... continued ...

Z  
 B  
 K  
 D  
 E  
 F  
 G  
 J  
 I  
 H  
 C  
 L  
 A  
 M  
 O



continuation of Figure 3



```

60          70          80          90          100          110          120
...      ...      ...      ...      ...      ...      ...
sapp      ...      ...      ...      ...      ...      ...      ...
sapp      ...      ...      ...      ...      ...      ...      ...
          STRAND E      STRAND F      STRAND G      STRAND H      STRAND I      STRAND J
          ...      ...      ...      ...      ...      ...      ...
3cna      ...      ...      ...      ...      ...      ...      ...
2ltn      ...      ...      ...      ...      ...      ...      ...
1ltn      ...      ...      ...      ...      ...      ...      ...
hcrp      ...      ...      ...      ...      ...      ...      ...
1lhp      ...      ...      ...      ...      ...      ...      ...
1ltn      ...      ...      ...      ...      ...      ...      ...

```

continuation of Figure 4

... continued further ...






Fig. 5a

1 2 / 1 6




Fig. 5b



13 / 16




Figure 6

1 4 / 1 6




Figure 7

15 / 16




Figure 8

16 / 16




Figure 9

RECTIFIED SHEET (RULE 91)

ISA/EP

## INTERNATIONAL SEARCH REPORT

Internatic Application No  
PCT/Gb 94/01802

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07K14/47 C07K1/00 A61K38/17 G01N33/68 C12P21/08  
C07K16/18 A61K51/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, vol.8, no.1, February 1994 pages 5 - 27 RUFINO S. D. ET AL. 'Structure-based identification and clustering of protein families and superfamilies' see page 18 - page 19; figure 3; table 4 ---	1-43
P,X	NATURE, vol.367, 27 January 1994, LONDON GB pages 338 - 345 EMSLEY J. ET AL. 'Structure of pentameric human serum amyloid P component' see the whole document --- -/--	1-43

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 November 1994

Date of mailing of the international search report

02-12-1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Espen, J

## INTERNATIONAL SEARCH REPORT

Internati Application No  
PCT/GB 94/01802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOCHIMICA ET BIOPHYSICA ACTA, vol.1160, no.3, 28 December 1992 pages 309 - 316 SWANSON S. J. ET AL. 'Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP)' see the whole document ---	12-15, 17-23, 25,26, 28-35, 37-41
X	LANCET THE, vol.2, September 1980, LONDON GB pages 606 - 609 DYCK R. F. ET AL. 'Amyloid P-component in human glomerular basement membrane' see the whole document ---	12,13, 15,17, 21-23, 25,41
X	J. EXP. MED., vol.172, July 1990 pages 13 - 18 BUTLER P. J. G. ET AL. 'Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin' cited in the application see the whole document ---	12,17,21
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.262, no.4, February 1987, BALTIMORE, MD US pages 1456 - 1460 HAMAZAKI HIDEAKI 'Ca 2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate' cited in the application see the whole document ---	12,17, 21-23, 25,26
X	JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.260, no.22, October 1985, BALTIMORE, MD US pages 12142 - 12147 POTEMPA L. A. ET AL. 'Effect of divalent metal ions and pH upon the binding reactivity of human serum amyloid P component, a C-reactive protein homologue, for zymosan' see the whole document ---	12,17, 18, 21-23, 25,26

## INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/GB 94/01802

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.261, December 1986, BALTIMORE, MD US pages 16518 - 16527 EINSPAHR H. ET AL. 'The crystal structure of pea lectin at 3.0-A resolution' cited in the application see the whole document ---	12-23, 28-31,33
X	US,A,5 221 628 (NORTHWESTERN UNIVERSITY) 22 June 1993  see the whole document ---	12,17, 21,25, 26,28, 32-35, 37-40
A	JOURNAL OF MOLECULAR BIOLOGY, vol.202, no.1, July 1988 pages 169 - 173 WOOD S.P. ET AL. 'A pentameric form of human serum amyloid P component' cited in the application ---	
A	JOURNAL OF CRYSTAL GROWTH, vol.90, 1988, AMSTERDAM NL pages 209 - 212 O'HARA B.P. ET AL. 'Crystallizations of human serum amyloid P component (SAP)' see the whole document -----	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/01802

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark : Although claims 42,43 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati/

Application No

PCT/GB 94/01802

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5221628	22-06-93	NONE	